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We previously determined the structure of the Pasteurella multocida Heddleston type 1 lipopolysaccharide
(LPS) molecule and characterized some of the transferases essential for LPS biosynthesis. We also showed that
P. multocida strains expressing truncated LPS display reduced virulence. Here, we have identified all of the
remaining glycosyltransferases required for synthesis of the oligosaccharide extension of the P. multocida
Heddleston type 1 LPS, including a novel -1,6 glucosyltransferase, a -1,4 glucosyltransferase, a putative
bifunctional galactosyltransferase, and two heptosyltransferases. In addition, we identified a novel oligosac-
charide extension expressed only in a heptosyltransferase (hptE) mutant background. All of the analyzed
mutants expressing LPS with a truncated main oligosaccharide extension displayed reduced virulence, but
those expressing LPS with an intact heptose side chain were able to persist for long periods in muscle tissue.
The hptC mutant, which expressed LPS with the shortest oligosaccharide extension and no heptose side chain,
was unable to persist on the muscle or cause any disease. Furthermore, all of the mutants displayed increased
sensitivity to the chicken antimicrobial peptide fowlicidin 1, with mutants expressing highly truncated LPS
being the most sensitive.
Pasteurella multocida is a gram-negative bacterial pathogen
that is the causative agent of fowl cholera in wild and domestic
birds. It is also responsible for a range of diseases in mammals,
including bovine hemorrhagic septicemia and swine atrophic
rhinitis (4). Serological classification of P. multocida strains is
based primarily on the capsular type, which divides strains into
serogroups A, B, D, E, and F (7, 26), and secondly on lipo-
polysaccharide (LPS) antigens that allow further classification
into 16 Heddleston serotypes (16). Fowl cholera is an econom-
ically important disease of poultry that occurs in most coun-
tries. The pathogenesis of infection is not well understood at
the molecular level, but initial colonization is thought to occur
via the host mucosa and may proceed to a rapid and severe
systemic disease that is generally fatal (4). Most fowl cholera
outbreaks in the poultry industry are associated with strains
belonging to serogroup A or F (4).
We showed previously that LPS is an important virulence
factor and that a complete LPS structure is required by P.
multocida strain VP161 for full virulence in chickens (14, 15).
However, it is unclear at what point during infection LPS is
critical for survival or how the length of the LPS structure
affects bacterial survival in vivo. The complete structures of the
LPSs expressed by VP161 (Heddleston type 1) and two other
fowl cholera-causing strains, X-73 (Heddleston type 1) and
Pm70 (Heddleston type 3), have been determined (29–31).
Like other pathogens, such as Haemophilus spp. and Neisseria
spp., P. multocida expresses LPS that lacks a polymeric O side
chain. The outer-core sugars of the LPS molecule, consisting of
the oligosaccharide extension and side branches, are thus the
most distal and exposed region of the LPS molecule. Compar-
ison of the LPS structure isolated from each of the three P.
multocida strains mentioned above revealed that the inner-
core sugars were highly conserved, but there was significant
variation in the outer sugars (29–31).
Unusually, all three of the P. multocida strains examined to
date simultaneously express LPS molecules with two different
inner-core structures, one containing a single phosphorylated
3-deoxy-D-manno-octulosonate (Kdo) residue and the other
containing two Kdo residues (shown for strain VP161 in Fig.
1B). In a previous study, we identified the transferases re-
quired for the assembly of the two inner-core glycoforms, A
and B (12). These comprised a Kdo transferase (KdtA) re-
quired for addition of the Kdo molecules to lipid A, a Kdo
kinase (KdkA) required to phosphorylate Kdo in glycoform A,
and two heptosyl-I-transferases (HptA and HptB), each of
which exclusively recognized different acceptor molecules (Fig.
1B) (12). Furthermore, we showed that despite the expression
of both glycoforms by wild-type P. multocida during growth in
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vivo and in vitro, mutants expressing LPS composed of only
glycoform B were able to cause systemic disease in chickens.
Additionally, we have recently identified a locus that is re-
quired for the addition of the terminal phosphocholine (PCho)
residues to the LPS molecule (14). Mutants lacking the termi-
nal PCho residues were less virulent than the parent strain but
were still able to cause disease (14).
In this study, we have completed the identification and char-
acterization of the transferases required for the assembly of
the oligosaccharide extension of the P. multocida VP161 LPS
molecule. Each of the glycosyltransferase genes predicted to be
involved in LPS assembly was inactivated, and the structure of
the LPS expressed by each of the mutants was determined.
These analyses identified a novel -1,6 glucosyltransferase and
a putative bifunctional galactosyltransferase capable of addi-
tion of a galactose to both the 4 and 6 positions of the fourth
heptose. Furthermore, we tested each mutant for virulence in
the natural chicken host. Lastly, we assessed the roles of
specific LPS components in conferring resistance to the
avian antimicrobial peptide fowlicidin 1, which is predicted
to be an important component of the chicken innate im-
mune system.
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and growth conditions. The bacterial
strains and plasmids used in this study are listed in Table 1. Escherichia coli was
grown routinely in Luria-Bertani broth. P. multocida and Mannheimia haemo-
lytica were grown in brain heart infusion (BHI) broth. Solid media were obtained
by the addition of 1.5% agar. When required, the media were supplemented with
spectinomycin (100 g/ml), streptomycin (50 g/ml), kanamycin (50 g/ml), or
tetracycline (2.5 g/ml for routine culturing or 8 g/ml for selection of P.
multocida transconjugants). For structural studies of LPS isolated from in vitro-
grown P. multocida and M. haemolytica, strains were grown in 2 liters of BHI,
which was incubated at 37°C with shaking until early log phase was reached. This
culture was then used to inoculate 24 liters of BHI in a 28-liter New Brunswick
Scientific fermentor. The cultures were grown at 37°C, with 24-liter min1 aer-
ation and stirring at 200 rpm for 18 h with 20% O2 saturation, and then the P.
multocida strains were incubated with hyaluronidase (1 g; Sigma) for 1 h at 37°C
to remove the capsule. The cells were killed by addition of phenol to 2% for 4 h
and harvested using a Sharples continuous centrifuge.
FIG. 1. Structures of the LPS molecules expressed by P. multocida strains Pm70 (A) and VP161 (B) and the glycoform C observed only in the
VP161 hptE mutant (C). Two inner-core LPS glycoforms were observed in Pm70 and VP161 wild-type strains, and the variable sections are boxed
in panel B and designated glycoform A and B. The gene known (B) or predicted (A and C) to be required for each biosynthetic step in the synthesis
of each molecule is shown below the linkages. The residues are Glc, glucose; Hep, heptose; Gal, galactose; GlcNAc, N-acetylglucosamine; and
PEtn, phosphoethanolamine.
VOL. 77, 2009 THE OUTER CORE OF P. MULTOCIDA LPS 1533
 o
n
 O
ctober 18, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
DNA manipulations. Restriction digestions and ligations were performed ac-
cording to the manufacturers’ instructions using enzymes obtained from NEB
(Beverley, MA) or Roche Diagnostics GmbH (Mannheim, Germany). Plasmid
DNA was prepared using alkaline lysis (3) and further purified using Qiagen
columns (Qiagen GmbH, Germany), while genomic DNA was prepared using
the cetyltrimethylammonium bromide method (2). PCR amplification of DNA
was performed using Taq DNA polymerase or the Expand High Fidelity PCR
System (Roche Diagnostics) and purified using the Qiagen PCR Purification Kit.
The oligonucleotides used in this study are listed in Table S1 in the supplemental
material. DNA sequences were determined on an Applied Biosystems 3730S
Genetic Analyzer and analyzed with Sequencher version 3.1.1 (GenCodes, Ann
Arbor, MI) or Vector NTI Advance version 10 (Invitrogen, Carlsbad, CA).
Construction of P. multocida mutants. For inactivation of each of the candi-
date glycosyltransferase genes in P. multocida strain VP161, we used the previ-
ously described single-crossover insertional-mutagenesis method, which utilizes
the  pir-dependent plasmid pUA826 (Table 1). For inactivation of all genes
except gatA, internal DNA fragments of each gene were amplified by PCR, using
the primers listed in Table S1 in the supplemental material; digested with SalI;
and ligated to SalI-digested pUA826. The correct recombinant plasmids (Table
1) were then mobilized into the recipient P. multocida strain AL435 (Table 1) by
conjugation from E. coli Sm10  pir (Table 1) as described previously (12).
Single-crossover insertion of the recombinant plasmid into each of the target
genes was confirmed by PCR using a genomic flanking primer in combination
with the primer BAP2782 located within the vector sequence (see Table S1 in the
supplemental material). For inactivation of gatA, bioinformatics analysis of the
region suggested that a single-crossover insertion within gatA may have polar
effects on the downstream gene hptE. Therefore, the SalI-digested internal gatA
fragment was ligated into the vector pUA826tpi (Table 1), which contains a
constitutive P. multocida promoter. Insertion of this construct into the genome
allowed transcription of the downstream hptE gene from the tpiA promoter
carried within the plasmid.
Construction of an M. haemolytica gctA mutant. An ortholog of the P. multo-
cida gatA (PM1116) gene was identified in the M. haemolytica PHL213 genome
using BLAST analysis (11). The protein encoded by M. haemolytica MHA_2524
displayed 74% amino acid identity to P. multocida GatA. The MHA_2524 gene
was amplified by PCR from chromosomal DNA of the M. haemolytica strain O1A
(Table 1) using the flanking primers BamHI-1F and EcoRI-1R (see Table S1 in
the supplemental material), which amplified a 1,267-bp fragment. Following
cloning into pBluescript (Table 1), inverse PCR was performed using the plasmid
as a template and primers that correspond to sequences within the PCR product
(Inv1R and Inv1F [see Table S1 in the supplemental material]). A kanamycin
(aph3) resistance cassette (19) was ligated to the gel-purified inverse-PCR prod-
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant description Source or reference
Strains
E. coli
DH5  80dlacZM15 (lacZYA-argF)U169 recA1 endA1 hsdR17(rK
 mK
) supE44
thi-1 gyrA relA1
Bethesda Research Laboratories
Sm10  pir Strain for propagation of pUA826 and its derivatives 27
M. haemolytica
O1A M. haemolytica wild-type strain 20
AA100 gctA mutant of M. haemolytica O1A This study
AA101 Complemented M. haemolytica gctA mutant This study
P. multocida
VP161 Serotype A:1; Vietnamese isolate from chickens 33
AL435 VP161 carrying a Tn916 insertion in gene pm1417; fully virulent (Tetr) 12
AL523 hptE mutant of AL435 This study
AL543 AL523 containing pAL99 This study
AL544 Complemented hptE mutant; AL523 containing pAL291 This study
AL554 gctB mutant of AL435 This study
AL574 gctA mutant of AL435 This study
AL669 PM0442 mutant of AL435 This study
AL696 hptC mutant of AL435 This study
AL725 gatA mutant of AL435 This study
AL804 Complemented gatA mutant; AL725 containing pAL445 This study
AL807 AL725 containing pAL99 This study
AL878 AL574 containing pAL99 This study
AL879 Complemented gctA mutant; AL574 containing pAL466 This study
AL880 AL554 containing pAL99 This study
AL881 Complemented gctB mutant; AL554 containing pAL468 This study
AL882 AL696 containing pAL99 This study
AL883 Complemented hptC mutant; AL696 containing pAL470 This study
Plasmids
pAL99 P. multocida expression plasmid (Kanr) 15
pAL291 Complete hptE gene cloned into pAL99 This study
pAL445 Complete gatA gene cloned into pAL99 This study
pAL466 Complete gctA gene cloned into pAL99 This study
pAL468 Complete gctB gene cloned into pAL99 This study
pAL470 Complete hptC gene cloned into pAL99 This study
pBluescript E. coli cloning vector Stratagene
pNF2176 M. haemolytica/E. coli shuttle plasmid (Ampr) 10
pNF2176-MH1116 Complete M. haemolytica gctA cloned into pNF2176 This study
pUA826 Mob; R6K replicon; Apr Strr Spcr; single-crossover insertional mutagenesis vector 6
pUA826tpi pUA826 derivative with a 240-bp PstI fragment containing the P. multocida tpiA
promoter; nonpolar mutagenesis vector
This study
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uct to generate the plasmid pMHglucosyltransferase::kan. This plasmid was
transformed into M. haemolytica by electroporation as described previously (9),
and transformants were selected on kanamycin. PCR was used to confirm the
insertional inactivation of gatA in the mutant, designated AA100, using the
primers 2F and 2R, specific to sequence flanking the gatA gene (see Table S1 in
the supplemental material).
In trans complementation of mutants. For complementation of the P. multo-
cida mutants, the complete open reading frame corresponding to each of the
mutated genes, with the exception of hptE, was amplified from P. multocida
VP161 genomic DNA using flanking oligonucleotides (see Table S1 in the sup-
plemental material). The amplified DNA fragments were then ligated into SalI-
and BamHI-digested pAL99 (Table 1) so that transcription of the gene would be
driven by the constitutive P. multocida tpiA promoter. For cloning of the hptE
gene, an EcoRV/SmaI deletion plasmid was generated from a previously con-
structed pAL99-derived plasmid containing both gatA and hptE genes (the orig-
inal fragment was amplified using oligonucleotides BAP3329 and BAP3330) so
that only the hptE gene remained intact. The nucleotide sequence of each of the
recombinant plasmids was determined to check the fidelity of the cloned gene,
and then each plasmid was transformed into the corresponding P. multocida
mutant, generating the complemented strains listed in Table 1. As a control, the
vector pAL99 was transformed separately into each mutant (Table 1). The M.
haemolytica gatA mutant was complemented by cloning the wild-type copy of
gatA into the M. haemolytica shuttle plasmid pNF2176, generating plasmid
pNF2176-MH1116 (Table 1). This plasmid was then used to transform the M.
haemolytica gatA mutant, generating the complemented mutant AA101.
Structural analyses of LPS. For analyses requiring small quantities of LPS,
plate-grown cells were killed with phenol (2% [wt/vol] final), washed four times
with H2O, lyophilized, resuspended in 200 l of H2O containing 5 g of pro-
teinase K, and incubated at 37°C for 5 h. The sample was heated to 70°C for 10
min, lyophilized, dissolved in 200 l of ammonium acetate buffer (20 mM, pH
7.4) containing 1 g of RNase and 2 g of DNase, incubated at 37°C for 5 h, and
then lyophilized. The crude LPS-containing samples were O deacylated by dis-
solving them in 200 l of anhydrous hydrazine and incubating them with stirring
at 37°C for 1.5 h. Excess hydrazine was destroyed by the addition of 5 volumes
of ice-cold acetone to the chilled samples, followed by repeated acetone washes.
The O-deacylated LPS (LPS-OH) pellet was redissolved in H2O and lyophilized.
For analyses requiring larger quantities, LPS was isolated and purified as
described previously (15). Briefly, freeze-dried killed cells were washed once with
ethanol and then twice each with acetone and light petroleum ether to remove
lipids and other lipophilic components. The washed cells were extracted by the
hot-phenol/water method, and following dialysis, the retentate was freeze-dried.
A 2% solution of this crude LPS was treated with DNase and RNase at 37°C for
4 h, followed by proteinase K treatment at 37°C for 4 h. Small peptides were
removed by dialysis. After being freeze-dried, the retentate was made up to a 2%
solution in water and centrifuged at 8,000  g for 15 min, yielding a pellet (8K
pellet), followed by further centrifugation of the supernatant at 100,000  g for
5 h. The pellet from this high-speed centrifugation, containing purified LPS, was
redissolved in water and freeze-dried. O-deacylated LPS and core oligosaccha-
ride were prepared as described previously (30). Sugars were identified as their
alditol acetate derivatives, and linkage analysis was determined following meth-
ylation analysis by gas-liquid chromatography–mass spectrometry (MS), as de-
scribed previously (15). Electrospray-MS and nuclear magnetic resonance
(NMR) analyses were performed as described previously (15).
Competitive-growth assays and assessment of virulence. Competitive-growth
assays were used to quantify the relative growth rates of the P. multocida strains
in vivo as described previously (13). Mutants were identified as attenuated for in
vivo growth if the relative competitive index (rCI) value was significantly less
than 1.0 (P 	 0.05 using a one-sided z test). Direct virulence trials in chickens
were performed as described previously (12). To check the identities of strains
recovered from infected chickens, muscle swabs and blood samples were plated
on BHI agar and BHI agar containing spectinomycin. To confirm the genotypes
of recovered strains, colony PCR was performed using a primer specific for DNA
flanking the mutated gene and one specific for the plasmid pUA826. To deter-
mine the LPS phenotypes of the recovered strains, proteinase K-treated whole-
cell lysate samples of pooled bacteria from each site were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized
by carbohydrate silver staining as described previously (32).
Antimicrobial peptide sensitivity assays. The chicken antimicrobial peptide
fowlicidin 1 (RVKRVWPLVIRTVIAGYNLYAIKKK) (34) was synthesized at
96% purity by Auspep (Parkville, Australia). The MICs of fowlicidin 1 for the P.
multocida parent and mutant strains were determined using a broth microdilu-
tion assay. Briefly, 100 l of fowlicidin 1 in 10 mM phosphate buffer, pH 7.4, was
added to 100 l of BHI containing approximately 1  105 CFU of exponential-
phase P. multocida. This concentration of BHI and phosphate buffer was found
to be optimal for both the overnight growth of P. multocida and the activity of the
fowlicidin 1. The assay mixtures were incubated overnight at 37°C, and the
absorbance was measured at 570 nm. The MIC was determined by averaging
the concentration of fowlicidin 1 that completely inhibited bacterial growth and
the next-lowest concentration that allowed some growth. Standard deviations
were calculated assuming that the MIC for each assay was equally likely to lie at
any value within this interval.
RESULTS
Bioinformatics analysis and nomenclature of LPS biosyn-
thesis genes in P. multocida VP161. The transferase genes
involved in the assembly of the oligosaccharide extension of
the P. multocida Pm70 LPS have been previously predicted
based on homology to known transferases, using BLAST and
the CAZy database of glycosyltransferases (Fig. 1A) (31).
However, the functions of these putative transferases have not
been confirmed experimentally. A comparison of the Pm70
and VP161 LPS structures (Fig. 1) allowed us to predict those
glycosyltransferases likely to be conserved between the two
strains. We showed previously that the Pm70 genes PM1138 to
PM1141 are not present in VP161 and that the corresponding
genomic region in strain VP161 contains the genes pcgABCD,
encoding proteins required for the addition of PCho to LPS
(14). This region also contained a gene that encoded a
glycosyltransferase displaying 70% identity to Pm70 LosA
(predicted to be a glucosyltransferase) and a gene encoding
a protein with 94% identity to the Pm70 protein PM1144,
predicted to be a putative heptosyl (IV) transferase. As predicted
from the LPS structural data, which showed that both Pm70 and
VP161 expressed LPSs with identical inner-core sugars, sequence
analysis of the VP161 glycosyltransferase genes PM1306 and rfaF
(Fig. 1) revealed that these genes were highly conserved between
VP161 and Pm70. Using BLAST (1), we were unable to predict a
glycosyltransferase involved in the addition of the -1,6-linked
glucose residue onto glycoform A (Fig. 1). However, using the
CAZy database of glycosyltransferases, two candidate glycosyl-
transferase genes were identified in the Pm70 genome sequence
(8). Each of these genes (PM1116 and PM1562) encoded glyco-
syltransferases with homologs in the genomes of the closely re-
lated veterinary pathogens M. haemolytica and Actinobacillus
pleuropneumoniae, which express a similar LPS structure with an
-1,6-linked glucose residue (5, 28). Moreover, there were no
homologues of either of these genes in Haemophilus influenzae,
which does not contain an -1,6-linked glucose in its LPS struc-
ture.
To standardize the nomenclature of the P. multocida en-
zymes involved in LPS biosynthesis, we have assigned gene
and protein names that specifically imply enzyme function. We
previously characterized two acceptor-specific heptosyltrans-
ferase genes (hptA and hptB) and a Kdo kinase gene (kdkA)
and named each with the first two letters designating the sugar
substrate and the third letter designating the enzyme action.
Thus, heptosyltransferase genes were designated hpt and the
Kdo kinase gene kdk (12). In this work, we have confirmed by
directed mutagenesis and structural analysis (see below) the
function of each of the transferases required for synthesis
of the outer oligosaccharide extension. Accordingly, PM1306,
encoding a 
-1,4 glucosyltransferase, has been named gctB;
PM1116, encoding an -1,6 glucosyltransferase, has been
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named gctA; rfaF, encoding a heptosyltransferase responsible
for the addition of the second heptose (Hep II), has been
renamed hptC; the gene encoding the novel galactosyltrans-
ferase has been named gatA; and PM1144, encoding the hep-
tosyltransferase required for the addition of the fourth heptose
(Hep IV), has been named hptE. Following this new nomen-
clature, the heptosyltransferase required for the addition of
the third heptose (Hep III) to the LPS, previously identified as
WaaQPM (annotated as PM1294 in Pm70), has been renamed
HptD (Fig. 1B) (15).
To confirm the function of the predicted transferases HptC,
GctA, GctB, HptE, and GatA, the gene encoding each trans-
ferase was mutated in P. multocida strain VP161 by allelic
exchange. The PM1562 gene was also inactivated in VP161, as
this gene was a possible candidate to encode the -1,6-linked
glucosyltransferase. However, MS analysis showed that the
mutant expressed wild-type LPS (data not shown), and it was
not investigated further. Each of the constructed mutants was
complemented with the appropriate full-length gene cloned
into the P. multocida expression vector pAL99 (Table 1). The
structure of the LPS expressed by each of the mutants and
complemented strains was then determined by combined MS
and NMR analyses.
Structural analysis of the LPS expressed by the gctBmutant.
Capillary electrophoresis-MS (CE-MS) analysis of the
LPS-OH derived from the gctB mutant confirmed a set of
truncated glycoforms that contained three heptose residues
but elaborated only one hexose residue (Table 2). Similarly,
MS analysis of the isolated core oligosaccharide identified only
two glycoforms consisting of Kdo, 3Hep and Kdo, 3Hep, Hex.
The majority of the Kdo-phosphate (P)-containing glycoforms
(glycoform A) elaborated a single hexose residue, which was
confirmed by methylation analysis to be the -1,6-linked glu-
cose. Methylation analysis revealed a terminal residue and a
2-substituted L-glycero-D-manno-heptose (LD heptose) residue
in approximately equimolar amounts, with smaller amounts of
terminal glucose, 3-substituted heptose, and 3,6-disubstituted
heptose, consistent with the MS data. NMR data were ob-
tained on a purified core oligosaccharide fraction (data not
shown) and confirmed the MS and methylation data. The
-glucose residue was identified by its characteristic spin sys-
tem in a total correlation spectroscopy experiment and was
TABLE 2. Negative-ion CE-ES-MS data and proposed compositions of LPS-OH from the P. multocida VP161 and M. haemolytica
O1A wild-type and mutant strains
Strain and descriptiona
Observed ions (m/z) Molecular ion
Proposed compositionb
(M-4H)4 (M-3H)3 (M-2H)2 Observed Calculated
AL435(parent) 743.8 991.9 1,488.6 2,979.1 2,977.6 2PCho, 3Hex, 4Hep, 2Kdo, lipid A-OH
749.4 999.2 1,499.4 3,001.0 2,999.5 2PCho, 4Hex, 4Hep, Kdo-P, lipid A-OH
780.2 1040.5 3,124.6 3,122.6 2PCho, 4Hex, 4Hep, Kdo-P-PEtn, lipid A-OH
AL696 (hptC mutant) 463.8 1,392.4 2Kdo, lipid A-OH
481.1 721.9 1,445.8 1,444.3 Hep, Kdo-P, lipid A-OH
803.0 1,608.0 1,606.5 Hex, Hep, Kdo-P, lipid A-OH
864.1 1,731.0 1,729.5 Hex, Hep, Kdo-P-PEtn, lipid A-OH
AL554 (gctB mutant) 608.8 913.8 1,829.5 1,828.6 3Hep, Kdo-P, lipid A-OH
649.7 975.1 1,952.2 1,951.7 3Hep, Kdo-P-PEtn, lipid A-OH
655.6 983.9 1,969.8 1,968.8 3Hep, 2Kdo, lipid A-OH
663.1 994.9 1,992.0 1,990.8 Hex, 3Hep, Kdo-P, lipid A-OH
704.1 1,056.3 2,114.9 2,113.8 Hex, 3Hep, Kdo-P-PEtn, lipid A-OH
AL574 (gctA mutant) 708.8 945.0 1,418.1 2,838.1 2,837.4 2PCho, 3Hex, 4Hep, Kdo-P, lipid A-OH
739.5 986.3 1,479.6 2,961.7 2,960.4 2PCho, 3Hex, 4Hep, Kdo-P-PEtn, lipid A-OH
743.9 992.0 1,488.6 2,979.3 2,977.6 2PCho, 3Hex, 4Hep, 2Kdo, lipid A-OH
AL523 (hptE mutant) - 709.8 1,064.8 2,132.4 2,131.0 Hex, 3Hep, 2Kdo, lipid A-OH
537.3 716.8 1,075.9 2,153.9 2,154.0 2Hex, 3Hep, Kdo-P, lipid A-OH
568.2 758.1 1,137.7 2,276.8 2,277.0 2Hex, 3Hep, Kdo-P, PEtn, lipid A-OH
- 953.3 - 2,862.9 2,861.7 2HexNAc, 3Hex, 3Hep, 2Kdo, lipid A-OH
AL725 (gatA mutant) 773.8 1,161.0 2,324.2 2,323.1 Hex, 4Hep, 2Kdo, lipid A-OH
781.1 1,172.0 2,346.1 2,345.1 2Hex, 4Hep, Kdo-P, lipid A-OH
821.6 1,233.8 2,468.7 2,468.2 2Hex, 4Hep, Kdo-P-PEtn, lipid A-OH
M. haemolytica O1A
(wild type)
704.7 940.1 1,410.6 2,823.1 2,822.5 3Hex, 5Hep, Kdo-P-PEtn, lipid A-OH
M. haemolytica
AA100 (gctA
mutant)
633.5 844.9 1,268.0 2,537.9 2,537.3 2Hex, 5Hep, Kdo-P, lipid A-OH
664.1 886.0 1,329.4 2,660.8 2,660.3 2Hex, 5Hep, Kdo-P-PEtn, lipid A-OH
a All mutants plus vector controls gave the same spectra as the corresponding mutants, and all complemented mutants gave the same spectra as the AL435 parent.
The LPS structural data for these strains have been omitted but are shown in full in Table S2 in the supplemental material.
b Average mass units were used for calculation of molecular weight based on proposed compositions as follows: lipid A, 952.00; Hex, 162.15; Hep, 192.17; Kdo, 220.18;
Kdo-P, 300.13; PEtn (phosphoethanolamine), 123.05; PCho, 165.05.
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shown to substitute the first heptose residue at the 6 position in
a nuclear Overhauser effect spectroscopy experiment. The
characteristic inter-nuclear Overhauser effect connectivity be-
tween the anomeric protons of the two glucose residues sub-
stituting heptose I in the wild type was absent from this mutant,
consistent with the absence of the 
-glucose residue. Comple-
mentation with an intact copy of gctB restored wild-type LPS
expression (see Table S2 in the supplemental material). There-
fore, these data confirm the function of GctB as the 
-1,4-
glucosyltransferase responsible for transfer of a glucose resi-
due to the 4 position of the proximal heptose residue.
Structural analysis of the LPS expressed by the hptC mu-
tant. CE-MS analysis of the LPS-OH isolated from the hptC
mutant confirmed the presence of a set of highly truncated
glycoforms (Table 2). Similarly, MS analysis of the isolated
core oligosaccharide identified a major glycoform Kdo-Hep
with lesser amounts of a Kdo-Hep-Hex glycoform. No LPS
glycoforms were identified that contained more than a single
heptose. This is consistent with HptC being the transferase
required for the addition of the branched heptose II to heptose
I. There was also an increase in the amount of the 2Kdo-lipid
A glycoform expressed by this mutant, which we attribute to a
polar effect of the mutation on the downstream gene encoding
HptA (the heptosyl-I-transferase required for glycoform A as-
sembly) (12). Interestingly, although the first heptose residue
was added to the Kdo-P inner-core glycoform (glycoform A),
only small amounts of a single hexose were able to be added to
this acceptor molecule, and there was no oligosaccharide ex-
tension beyond this point. This single hexose was confirmed by
methylation analysis to be the -1,6-linked glucose. Thus, there
is no addition of the 
-1,4-glucose residue in this mutant and
no further assembly of the main chain oligosaccharide, indi-
cating that GctB is highly dependent on the correct conforma-
tion of the acceptor molecule. When the hptC mutant was
complemented with intact hptC, wild-type LPS expression was
restored (see Table S2 in the supplemental material). There-
fore, these data confirm that HptC is the heptosyl II trans-
ferase responsible for addition of the second heptose to the
first heptose residue of both glycoforms A and B.
Structural analysis of the LPS expressed by P. multocida and
M. haemolytica gctA mutants. CE-MS analysis of LPS-OH de-
rived from the P. multocida gctA mutant strain revealed a fully
extended glycoform B, but glycoform A was 162 atomic mass
units smaller than that expressed by the parent, consistent with
the absence of a single hexose residue (see Fig. S1 and Table
S2 in the supplemental material). Methylation analysis of the
LPS expressed by the mutant revealed the appearance of a
3,4-disubstituted heptose residue with the concomitant loss of
the 3,4,6-trisubstituted heptose residue, confirming and ex-
tending the MS data. Finally, NMR analysis of the purified
core oligosaccharide revealed that signals diagnostic for the
-glucose residue were absent. Examination of the anomeric
region of the 1H-NMR spectrum (Fig. 2) clearly revealed that
the signal diagnostic for the anomeric proton of the -glucose
residue at 5.21 ppm in the parent spectrum (Fig. 2a) was absent
in the gctA mutant spectrum (Fig. 2b). Signals in the parent
spectrum that are due to the variable presence of the -glucose
residue (present in glycoform A but not glycoform B) affecting
their chemical shifts in the parent are shown in Fig. 2a. There-
fore, in the gctA mutant spectrum, there is only one signal for
each of these residues, as the heterogeneous -glucose residue
of the parent is now completely absent. Complementation in
trans restored the wild-type LPS glycoform (see Table S2 in the
supplemental material). Therefore, these data confirmed that
P. multocida GctA is an -1,6 glucosyltransferase.
The identification of this novel -1,6-linked glucosyltrans-
ferase was corroborated in the related veterinary pathogen
M. haemolytica (formerly Pasteurella haemolytica), which
also expresses LPS with a similar -1,6-linked glucose resi-
due on the first heptose. We inactivated the homologous
gene (MHA_2524), in the M. haemolytica strain O1A to gen-
erate the gctA mutant AA100. As was observed in P. multocida,
the M. haemolytica gctA mutant also expressed LPS that was
162 atomic mass units smaller than the LPS expressed by the
parent strain, consistent with the absence of a single hexose
residue (Table 2). This hexose was confirmed by methylation
and NMR analysis to be the -1,6-linked glucose (data not
shown). Wild-type LPS expression was restored when the M.
haemolytica gctA mutant was complemented in trans with a
functional copy of gctA (see Table S2 in the supplemental
material). Therefore, these data confirm the function of GctA
as the -glucosyltransferase responsible for transfer of a glu-
cose residue to the 6 position of the proximal heptose residue
in LPS expressed by both P. multocida and M. haemolytica.
Structural analysis of the LPS expressed by the hptE mu-
tant. CE-MS analysis of the LPS-OH derived from the hptE
mutant strain revealed ions consistent with a set of truncated
LPS molecules lacking the terminal (PCho-Gal)2-Hep IV moi-
ety (Table 2). Methylation analysis of the mutant strain re-
vealed the presence of terminal glucose, terminal LD-heptose,
2-subsituted heptose, 3,4-disubstituted LD-heptose, and 3,4,6-
trisubstituted LD-heptose residues in an approximate ratio of
4:2:2:1:1, confirming and extending the MS data. Complemen-
tation of the hptE mutant restored the production of wild-type
LPS (see Table S2 in the supplemental material). These data
confirmed the function of HptE as the heptosyl (IV) trans-
ferase.
Interestingly, the methylation analysis also revealed lesser
amounts (approximately 15%) of a 4-substituted glucose resi-
due, along with 3-substituted and terminal galactose residues
and 3- and 4-substituted N-acetyl-glucosamine residues. Exam-
ination of the MS data revealed small amounts of ions consis-
tent with the presence of a novel P. multocida LPS glycoform
consisting of lipid A-OH, 2Kdo, 3Hep, 3Hex, 2HexNAc from
an LPS-OH sample and Kdo, 3Hep, 3Hex, 2HexNAc from a
core oligosaccharide sample. These data indicate that in the
hptE mutant, approximately 15% of the LPS molecules contain
a novel LPS extension from the 
-D-glucose comprising 
-Gal-
(1-4)-
-GlcNAc-(1-3)-
-Gal-(1-3)-
-GlcNAc-(1-4) (Fig. 1C).
Structural analysis of the LPS expressed by the gatA mu-
tant. CE-MS analysis of the LPS-OH derived from the gatA
mutant revealed ions consistent with the loss of the two ter-
minal PCho residues and two galactose residues (Table 2).
Methylation analysis indicated the presence of terminal glu-
cose, 6-substituted glucose, terminal LD-heptose, 3,4-disubsti-
tuted heptose, and 3,4,6-trisubstituted heptose residues, con-
sistent with the MS data. Thus, both the 1,4- and 1,6-linked
galactose sugars are absent from the LPS expressed by the gatA
mutant. Complementation with a functional gatA gene re-
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FIG. 2. Anomeric regions of the 1H-NMR spectra of core oligosaccharide from the VP161 wild-type parent strain (a) and the gctA mutant
AL574 (b). The anomeric resonances are as indicated. The asterisks refer to heterogeneity in the parent strain caused by the variable presence of
the -glucose residue, which affects chemical shifts of the marked anomeric resonances and which is absent in the mutant strain, where the
-glucose residue is absent. The insets show the structures for the wild-type and mutant strains. The spectra were recorded in D2O at 25°C and
referenced to the deuterated water signal at 4.78 ppm.
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stored expression of the wild-type LPS (see Table S2 in the
supplemental material).
Virulence of the P. multocida mutants expressing modified
LPS. All mutants were shown to grow normally in vitro, indi-
cating that the LPS truncations did not affect cell viability or
the growth rate. The ability of each of the mutants to grow in
vivo was assessed using competitive-growth assays. All mutants
except the gctA mutant (AL574) were strongly attenuated for
growth in chickens following intramuscular injection (Table 3).
The mutants were then assessed by direct challenge for the
ability to cause fowl cholera in chickens. Each P. multocida
strain was injected into the pectoral muscles of chickens, and
each bird was monitored at regular intervals for signs of dis-
ease (Table 3). All birds injected with the parent strain AL435
showed signs of disease within 16 h and were euthanized by
36 h (average time to death, 28  6 h). Similarly, all birds
injected with the gctA mutant were euthanized by 28 h (average
time to death, 24  3 h), demonstrating that expression of
GctA is not required for P. multocida to cause fowl cholera.
None of the birds injected with the hptC mutant showed any
clinical signs over the 66 h of the experiment, and no bacteria
were recovered from the blood of these birds. Thus, mutants
expressing LPS truncated at the first heptose residue are avir-
ulent. However, all of the birds injected with the gctB, hptE,
and gatA mutants eventually showed clinical signs of fowl chol-
era, with the first signs appearing at approximately 40 h (Table
3). Both blood and muscle (injection site) samples were recov-
ered from a minimum of four birds within each group at the
time of euthanasia. Within these groups, the mutant strain
could be recovered from all muscle samples, and the majority
of birds examined at necropsy had visible muscle lesions at the
site of injection. Therefore, the gctB, hptE, and gatA mutants
can all survive and grow within the muscles of infected chick-
ens for at least 66 h.
Blood samples were taken from chickens injected with either
the gctB or gatA mutant at the time of euthanasia and plated
out onto both nonselective and selective media. Only very
small numbers of spectinomycin-resistant P. multocida bacteria
were recovered from some birds within each group, but in all
cases, spectinomycin-sensitive P. multocida could be recovered,
suggesting the presence of wild-type revertants. Similarly,
SDS-PAGE analysis of proteinase K-treated whole-cell lysates
of the pooled bacteria recovered from the blood showed only
the presence of wild-type LPS (data not shown). Finally, PCR
analysis of bacteria isolated from the blood of these birds
detected only wild-type P. multocida (data not shown). Taken
together, these data indicate that, although trace levels of the
gctB and gatA mutants were detected in the blood, the primary
causative agent of disease observed in birds within these
groups was wild-type revertant bacteria.
Blood samples were taken from chickens infected with the
hptE mutant and plated onto nonselective and selective agar.
Both spectinomycin-resistant and spectinomycin-sensitive bac-
teria were identified. PCR and SDS-PAGE analysis revealed
that both mutant and wild-type bacteria were present in ap-
proximately equal numbers (data not shown). Taken together,
these data indicate that the gctB, hptE, and gatA mutants can
survive and grow in muscle for long periods. Furthermore, the
hptE mutant was able to grow to a high level in the blood of
chickens, but the gctB and gatA mutants were highly attenuated
for growth in blood.
Sensitivities of LPS mutants to the antimicrobial peptide
fowlicidin 1. Antimicrobial peptides are a critical component
of the innate immune system of higher organisms (18). A
TABLE 3. Relative in vivo growth rate (rCI), as determined by competitive-growth assays, and virulence, as determined by direct challenge,
of parent and mutant strains
Strain Competitive-growthassay rCIa
Direct virulence challenge
Dose (CFU) Deathsb Time to death(h)
Bacteria recovered
Muscle Blood
AL696 (hptC) 0.0 60 0/7c NAd NDe NDf
0.0
AL554 (gctB) 0.0 90 7/7 66f WT-rg and AL554 WT-r and trace amounts
of AL5540.0
AL574 (gctA) 1.19 50 7/7 24  3 AL574 AL574
1.16
AL523 (hptE) 0.0 110 7/7 66f AL523 WT-r and AL523
0.09
AL725 (gatA) 0.0 50 7/7 66f AL725 WT-r and trace amounts
of AL7250.0
AL435 (parent) 0.88 60 7/7 28  6 AL435 AL435
1.33
1.29
0.83
a The values represent the rCIs calculated for individual animals, determined by dividing the in vivo competitive index (CI) by the in vitro CI. Each CI value was
determined by dividing the output mutant/wild-type ratio by the input mutant/wild-type ratio. All rCI values under 0.1 have a P value of 	 0.001 as calculated using
a one-tailed z test. All other values have P values of 0.05.
b All birds showing terminal signs of fowl cholera were euthanized in accordance with animal ethics requirements.
c The survival of chickens infected with AL696 was statistically different from that of all other groups (Fisher’s exact test; P 	 0.001).
d NA, not applicable.
e ND, not done.
f Some of the birds in this group displayed only early signs of fowl cholera infection at the designated end of the experiment. Therefore, an accurate time to death
cannot be calculated.
g WT-r, wild-type revertant.
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number of chicken antimicrobial peptides have been charac-
terized, including members of the 
-defensin (17) and cathe-
licidin (34) families. A critical first step in the action of cationic
antimicrobial peptides is the interaction of the peptide with
LPS; alteration of LPS structure can therefore affect suscepti-
bility to antimicrobial peptides (21, 25). We have shown re-
cently that the terminal PCho residues on the P. multocida LPS
contribute to resistance to fowlicidin 1 (14). Accordingly, we
determined the sensitivity of the P. multocida parent strain
AL435 and each of the mutants constructed in this study to the
bactericidal action of fowlicidin 1 (Fig. 3).
All of the mutants expressing truncated LPS were more
sensitive to the bactericidal action of fowlicidin 1, although the
difference for the gctA mutant was slight. The hptC mutant was
the most sensitive strain, while the hptE, gctB, and gatA mu-
tants showed intermediate levels of sensitivity, comparable to
that of a mutant (pcgC) lacking the terminal PCho substituents
(Fig. 3) (14). These data indicate that the terminal PCho res-
idues are important for maximal resistance, while the other
main-chain oligosaccharides have a minor effect on sensitivity
to fowlicidin 1. However, loss of the heptose side chain signif-
icantly increased susceptibility.
DISCUSSION
The structures of the P. multocida strain VP161 (Heddleston
LPS type 1) and Pm70 (Heddleston LPS type 3) LPS molecules
were determined previously (30, 31). We predicted the genes
required for synthesis of the VP161 LPS and inactivated each
of the genes in VP161. Each of the mutants expressed modified
LPS, with clear differences observed in the ratios and types of
sugars present.
The most subtle difference was observed in the LPS ex-
pressed by the gctA mutant (AL574), which differed from wild-
type LPS only in the expression of a glycoform A lacking the
-D-glucose. Directed mutagenesis of the homologous gene
(MHA_2524) in M. haemolytica and structural analysis of the
LPS expressed by the mutant also confirmed GctA as the -1,6
glucosyltransferase in this species. The presence of the -D-
glucose on the first heptose of the LPS is only observed in
veterinary pathogens within the Pasteurellaceae, including P.
multocida, M. haemolytica, Haemophilus parasuis, and A.
pleuropneumoniae (28), and is not observed in human patho-
gens of the family, such as H. influenzae. The reason for this
specificity is currently unclear. The P. multocida gctA mutant
grew as well as the wild type in our fowl cholera model, but the
possibility remains that this sugar is required for survival in
some other as-yet-undefined niche.
The hptC mutant expressed the most highly truncated LPS,
with a structure not extended beyond HepI except for addition
of the -1,6 glucose on glycoform A (Fig. 1 and Table 2).
Structural analysis indicated that this severe truncation was
due to the failure of another transferase, GctB, to add glucose
to the main-chain oligosaccharide. Previously, we showed that
inactivation of HptD (Fig. 1) also affected GctB activity, re-
sulting in approximately 90% of the LPS lacking extension
beyond the first heptose residue (15). Therefore, GctB can
only function efficiently when the triheptose side chain is in-
tact, confirming the critical reliance of this transferase on the
correct conformation of the acceptor molecule.
HptE was identified as the heptosyltransferase required for
the addition of the fourth heptose to glycoforms A and B.
Interestingly, this mutant expressed a small amount of a novel
LPS glycoform (glycoform C) that differed from glycoforms A
and B in the outer-core region. In many wild-type strains of
Neisseria spp. and H. influenzae, LPS glycoforms have been
detected that contain the same terminal trisaccharide, 
-Gal-
(1-4)-
-GlcNAc-(1-3)-
-Gal, as that observed in glycoform C,
FIG. 3. Sensitivities of P. multocida strains to killing by the action of fowlicidin 1. The MIC of fowlicidin 1 was determined by growth of each
strain in 50% BHI containing increasing concentrations of fowlicidin 1. The strains tested were the parent (AL435), PM0442 mutant (strain AL669
with an insertion in a gene unrelated to LPS biosynthesis), pcgC mutant (PCho strain [14]), gatA mutant (AL725), hptE mutant (AL523), gctB
mutant (AL554), gctA mutant (AL574), and hptC mutant (AL696). The MIC was determined by averaging the concentration of fowlicidin 1 that
completely inhibited bacterial growth and the next-lowest concentration that allowed some growth. Standard deviations were calculated assuming
that the MIC for each assay was equally likely to lie at any value within this interval. The reported values are the MICs for three replicates, and
the error bars show 1 standard deviation.
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which mimics paragloboside and other glycosphingolipids ex-
pressed in mammalian tissues (22, 23). The glycosyltrans-
ferases required for the assembly of this trisaccharide in H.
influenzae were identified when genes from the lsg locus were
expressed in E. coli (24). A search of the P. multocida Pm70
genome sequence identified five genes within a single locus
(PM0507 to -0513) that shared significant identity with genes
within the H. influenzae lsg locus. The H. influenzae LsgA,
LsgB, LsgD, LsgE, and LsgF proteins showed identity to
PM0507 (82%), PM0508 (59%), PM0509 (79%), PM0511
(76%), and PM0512 (88%), respectively. The genes encoding
these proteins are also present in P. multocida strain VP161,
and based on homology with known transferases, we predict
that PM509, PM0511, and PM0512 are the glycosyltransferases
required for assembly of the terminal trisaccharide in glyco-
form C (Fig. 1C). We were unable to show definitively the
involvement of the PM507-PM513 locus in the expression of
glycoform C in the hptE mutant, as it is currently not possible
to make multiple directed mutants in P. multocida.
The glycosyltransferase responsible for addition of the ga-
lactose residues onto glycoforms A and B was identified as
GatA. Inactivation of gatA resulted in a mutant strain that
expressed LPS lacking both the terminal galactose sugars and
PCho residues. Therefore, either GatA is a galactosyltrans-
ferase that is capable of adding both galactose residues to the
terminal (IV) heptose or, alternatively, GatA is responsible for
addition of one of the galactose residues and failure to add this
sugar precludes the action of an as-yet-unidentified galactosyl-
transferase encoded elsewhere on the VP161 genome. In the
sequenced P. multocida Pm70 strain, a similar addition to the
LPS structure is predicted, except that two glucose residues are
added to the fourth heptose. However, the LPS locus in Pm70
encodes only one glucosyltransferase, LosA, and a search of
the entire genomic sequence failed to identify a second glu-
cosyltransferase predicted to have the specificity required for
this addition. Therefore, we predict that both LosA and GatA
are bifunctional transferases, capable of adding galactose
(GatA) or glucose (LosA) to both the 4 and 6 positions of the
distal heptose residue on the LPS structure.
Mutants expressing altered LPS were tested both for viru-
lence in chickens and resistance to fowlicidin 1. All mutants,
with the exception of gctA, were severely attenuated for in vivo
growth. The hptC mutant, which expressed the most highly
truncated LPS, caused no disease in birds at the dose tested
and was highly sensitive to the action of fowlicidin 1, indicating
that the heptose side chain is critical for the ability to cause
disease and resistance to fowlicidin 1. As the triheptose resi-
dues are uncharged, we predict that they form a steric barrier
against the initial interaction of fowlicidin 1 with lipid A.
The gctB and gatA mutants were highly attenuated for in vivo
growth, as determined by competitive-growth assays, and al-
though birds directly challenged with the gctB or gatA mutant
developed fowl cholera late in the trial, the data indicate that
the systemic infection was caused by wild-type revertant P.
multocida. Interestingly, gctB and gatA mutants could survive
for long periods (several days) in the muscle but were unable
to persist in the blood. While the single-crossover insertional
mutants constructed in this work have a very low level of
instability in vitro (and are completely stable in the presence of
antibiotic selection), the ability of these mutants to survive and
multiply in the muscles of birds in the absence of antibiotic
selection for many days allows wild-type revertants to arise.
Once these revertants are generated, they have a significant
selective advantage in vivo and can enter the bloodstream,
multiply rapidly, and cause systemic disease. Similar instability
leading to delayed disease has been observed previously with a
hptD (WaaQPM) transposon mutant (15). While it would have
been of interest to test the virulence of more stable double-
crossover mutants within each of these genes, we have been
unable to construct these mutants. Indeed, there are no pub-
lished reports of double-crossover mutants in this P. multocida
strain.
We have shown previously that the terminal PCho residues
on P. multocida LPS are important for maximal resistance to
the chicken antimicrobial peptide fowlicidin 1, and it is likely
that the positive charge on PCho is critical in repelling the
cationic fowlicidin 1 (14). The gctB and gatA mutants were
slightly more susceptible to the action of fowlicidin 1 than
mutants lacking just the terminal PCho residues, suggesting
that these sugars in the main-chain oligosaccharide extension
contribute marginally to antimicrobial peptide resistance.
All birds infected with the hptE mutant showed signs of fowl
cholera, but again, at later times than birds infected with the
parent strain. However, birds infected with the hptE mutant
had significant amounts of both mutant and wild-type revertant
P. multocida in the bloodstream. While we cannot completely
exclude the possibility that the survival of the hptE mutant was
assisted by the presence of wild-type bacteria, we believe this is
unlikely. A number of different LPS mutants were tested in
chickens, and in all cases wild-type revertants were present, yet
not all mutants were able to survive in the blood of infected
birds. This finding suggests that the hptE mutant has a unique
component that contributes to its survival in the host, and we
propose that it is the expression of glycoform C LPS.
In conclusion, we have identified all of the transferases re-
quired for synthesis of the main outer-core oligosaccharide
extension of the P. multocida strain VP161 LPS. We have
identified a novel -1,6 glycosyltransferase (GctA) and a pre-
dicted bifunctional galactose transferase (GatA). The hptC
mutant was completely attenuated and significantly more sus-
ceptible to fowlicidin 1 than any of the other mutants tested,
indicating that the heptose side chain is critical for survival in
the host. All mutants expressing a truncated main oligosaccha-
ride extension (gctB, hptE, and gatA) could survive in the mus-
cle for long periods but were more susceptible than the wild-
type strain to the action of fowlicidin 1. While the gctB and
gatA mutants displayed significantly reduced growth within the
blood, the hptE mutant, which expresses the novel glycoform
C, was able to survive and multiply within the blood of chickens
until late in infection and may be capable of causing disease. It
is interesting to speculate that glycoform C may be critical in
some as-yet-undefined host environments; we are currently
investigating this possibility.
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